성장을 멈추지 마세요

체험은 만족하셨나요?

현재 45,766명이 마이메르시로 공부 중이에요

지식 자료를 소장하고 멋진 의료인으로 성장하세요

학습 자료 둘러보기 →
Tuberculosis | 마이메르시 MyMerci
제안하기

뭔가 하고 싶은 말이 있는거야?

0 / 2000
컨텐츠 수정하기

컨텐츠 내용을 수정할 수 있습니다

수정하기
닫기

Tuberculosis

NCLEX Review Guide: Tuberculosis in Pregnancy

Pathophysiology and Transmission

Tuberculosis Basics

  • Tuberculosis (TB) is caused by Mycobacterium tuberculosis, an aerobic bacterium that primarily affects the lungs but can involve other organs. During pregnancy, TB can have significant implications for both maternal and fetal health due to physiologic and immunologic changes that occur.
  • TB is transmitted through inhalation of airborne droplet nuclei containing M. tuberculosis that are expelled when an infected person coughs, sneezes, speaks, or sings. Close, prolonged contact is typically required for transmission.

Key Points

  • Pregnancy does not increase susceptibility to TB infection, but can increase risk of progression from latent to active TB.
  • TB can be transmitted vertically (mother to fetus) but is rare; congenital TB occurs in less than 1% of cases.

Pregnancy-Specific Considerations

  • Pregnancy-related immunologic changes, including decreased cell-mediated immunity and T-helper 1 cell activity, may contribute to reactivation of latent TB or progression of primary infection to active disease.
  • Physiologic changes during pregnancy, such as increased oxygen consumption, decreased functional residual capacity, and diaphragmatic elevation, can mask TB symptoms or make them less specific.

Key Points

  • Highest risk of TB reactivation occurs during the early postpartum period when immune function returns to normal.
  • Extrapulmonary TB occurs in approximately 10-15% of pregnant women with TB and may involve the placenta.

Diagnosis and Screening

Screening Methods

  • Tuberculin Skin Test (TST) and Interferon-Gamma Release Assay (IGRA) are the primary screening tools for latent TB infection (LTBI). Neither test is affected by pregnancy, and both are considered safe during all trimesters.
  • For TST, a positive result is an induration of ≥10 mm in high-risk populations, including pregnant women from TB-endemic regions. For IGRA, interpretation is based on the specific test's cutoff values and is not altered by pregnancy status.

Key Points

  • Universal TB screening is not recommended for all pregnant women; risk-based screening should be performed at the first prenatal visit.
  • Risk factors warranting screening include HIV infection, close contact with active TB cases, birth or residence in TB-endemic regions, and healthcare workers.

Diagnostic Methods for Active TB

  • Chest radiography with abdominal shielding is considered safe during pregnancy and should not be delayed if TB is suspected. The radiation exposure from a single chest X-ray is well below the threshold associated with fetal harm.
  • Sputum microscopy for acid-fast bacilli (AFB) and culture remain the gold standard for diagnosis of pulmonary TB. Nucleic acid amplification tests (NAATs) such as Xpert MTB/RIF provide rapid results and can detect drug resistance.

Key Points

  • The clinical presentation of TB during pregnancy may be atypical; maintain high index of suspicion for TB in high-risk pregnant women with persistent respiratory symptoms.
  • Extrapulmonary TB diagnosis may require additional tests such as lymph node biopsy, cerebrospinal fluid analysis, or imaging studies depending on the site involved.

Clinical Scenario

A 28-year-old woman at 20 weeks gestation presents for prenatal care. She recently immigrated from a TB-endemic country and reports a 3-week history of productive cough, night sweats, and unintentional weight loss. Her TST shows 18mm induration, and chest X-ray reveals upper lobe infiltrates with cavitation. How would you proceed with diagnosis and management?

Assessment: High suspicion for active pulmonary TB based on symptoms, risk factors, positive TST, and radiographic findings.

Nursing Actions: Collect three sputum samples for AFB smear and culture, implement airborne precautions, and consult infectious disease specialist for initiation of appropriate TB treatment regimen safe for pregnancy.

Treatment During Pregnancy

Pharmacological Management

  • First-line drugs for active TB during pregnancy include isoniazid (INH), rifampin (RIF), and ethambutol (EMB), which are considered safe. Streptomycin is contraindicated due to risk of ototoxicity in the fetus. Pyrazinamide (PZA) safety is debated but often included in regimens.
  • Treatment of latent TB infection (LTBI) during pregnancy typically consists of INH monotherapy for 9 months with pyridoxine (vitamin B6) supplementation to prevent peripheral neuropathy.

Comparison of TB Medications in Pregnancy

Medication FDA Pregnancy Category Safety Profile Special Considerations
Isoniazid (INH) C Generally safe Must be given with pyridoxine (vitamin B6); monitor LFTs
Rifampin (RIF) C Generally safe May reduce effectiveness of hormonal contraceptives postpartum
Ethambutol (EMB) B Safe Monitor visual acuity and color discrimination
Pyrazinamide (PZA) C Limited data; used in many countries WHO recommends use; some guidelines recommend avoiding
Streptomycin D Contraindicated Associated with congenital deafness

Key Points

  • Treatment of active TB should never be delayed due to pregnancy; untreated TB poses greater risks to mother and fetus than treatment side effects.
  • Directly Observed Therapy (DOT) is recommended to ensure adherence and monitor for adverse effects.

Treatment Monitoring and Side Effects

  • Monthly clinical assessment should include evaluation of treatment response, medication adherence, and monitoring for adverse effects. Baseline and periodic liver function tests are essential, particularly for pregnant women on isoniazid.
  • Common side effects of TB medications during pregnancy include hepatotoxicity (INH, RIF, PZA), peripheral neuropathy (INH), gastrointestinal disturbances, and hypersensitivity reactions. Drug-induced hepatitis requires immediate discontinuation of hepatotoxic medications.

Memory Aid: First-Line TB Drugs in Pregnancy

Remember "RIPE minus S":
R - Rifampin (safe)
I - Isoniazid (safe with B6)
P - Pyrazinamide (use with caution)
E - Ethambutol (safe)
Avoid S - Streptomycin (contraindicated)

Key Points

  • Pyridoxine (vitamin B6) supplementation (25-50 mg daily) is mandatory for pregnant and breastfeeding women on isoniazid to prevent peripheral neuropathy.
  • Multidrug-resistant TB (MDR-TB) in pregnancy requires specialist consultation; treatment regimens must be individualized based on resistance patterns and pregnancy considerations.

Treatment Procedures

  1. Perform comprehensive TB risk assessment at first prenatal visit
  2. Conduct appropriate screening tests (TST or IGRA) for high-risk women
  3. For positive screening tests, obtain chest X-ray with abdominal shielding
  4. Collect sputum samples for AFB smear, culture, and drug susceptibility testing if active TB is suspected
  5. Initiate appropriate treatment regimen promptly after diagnosis
  6. Implement infection control measures (airborne precautions) for contagious TB
  7. Monitor treatment adherence, preferably through DOT
  8. Assess for medication side effects at each visit
  9. Perform monthly clinical evaluations and appropriate laboratory monitoring
  10. Continue treatment for recommended duration regardless of delivery timing

Maternal and Fetal Outcomes

Maternal Complications

  • Untreated TB during pregnancy is associated with increased maternal morbidity and mortality. Complications include anemia, pneumonia, respiratory failure, and postpartum hemorrhage.
  • TB increases the risk of pregnancy-related complications such as preeclampsia, miscarriage, and premature rupture of membranes. The risk is particularly high with miliary or advanced pulmonary TB.

Key Points

  • HIV co-infection significantly increases the risk of TB reactivation during pregnancy (10-fold higher) and requires coordinated management of both conditions.
  • Postpartum period carries increased risk for TB exacerbation due to physiologic and immunologic changes; close monitoring is essential during this period.

Fetal and Neonatal Considerations

  • Untreated maternal TB is associated with increased risk of low birth weight, preterm birth, intrauterine growth restriction, and perinatal mortality. Appropriate TB treatment significantly reduces these risks.
  • Congenital TB is rare but can occur through hematogenous spread via the umbilical vein or through aspiration of infected amniotic fluid. Placental TB can occur without fetal infection.

Key Points

  • Neonates born to mothers with untreated active TB should be evaluated for congenital TB regardless of symptoms.
  • BCG vaccination should be considered for infants in TB-endemic regions or those who cannot be separated from mothers with active TB.

Nursing Management

Intrapartum and Postpartum Care

  • Women with active TB who have received at least 2 weeks of effective therapy are generally considered non-infectious. TB status alone is not an indication for cesarean delivery; obstetric indications should guide delivery method.
  • Postpartum separation of mother and infant is recommended only if the mother has untreated active TB, was recently diagnosed and has received less than 2 weeks of therapy, or has suspected drug-resistant TB.

Key Points

  • Women with active TB should wear surgical masks during labor if less than 2 weeks into treatment; healthcare providers should use N95 respirators.
  • Breastfeeding is not contraindicated for women on TB treatment; the amount of medication in breast milk is insufficient to treat or prevent TB in the infant.

Newborn Management

  • Infants born to mothers with active TB should be evaluated with thorough physical examination, chest radiography, and other tests as indicated. Congenital TB can present with hepatosplenomegaly, respiratory distress, fever, and lymphadenopathy.
  • Prophylactic isoniazid (10 mg/kg daily) should be given to infants born to mothers with active TB until maternal disease is deemed non-infectious. After excluding active TB in the infant, continue INH for 3-4 months, then perform TST.

Memory Aid: Signs of Congenital TB - "TUBERCULOSIS"

Temperature instability
Unusual respiratory distress
Bulging fontanelle (TB meningitis)
Enlarged liver and spleen
Respiratory difficulty
Cough
Underweight/poor feeding
Lymphadenopathy
Otitis (middle ear infection)
Skin lesions
Irritability
Sepsis-like presentation

Key Points

  • If TST is negative and infant is asymptomatic after 3-4 months of INH, prophylaxis can be discontinued and BCG vaccination considered if indicated.
  • If mother and infant are separated, expressed breast milk can still be provided to the infant as TB is not transmitted through breast milk.

Patient Education and Support

  • Educate pregnant women about the importance of TB treatment adherence for maternal and fetal health. Emphasize that properly treated TB rarely poses risks to the pregnancy or newborn.
  • Provide culturally sensitive counseling regarding infection control measures, medication side effects, and the importance of follow-up care. Address concerns about stigma associated with TB diagnosis.

Key Points

  • Ensure patients understand the difference between active TB disease and latent TB infection, and the importance of completing the full course of therapy.
  • Connect patients with social services as needed for housing assistance, nutritional support, and other resources that may improve treatment adherence.

Commonly Confused Points

Active TB vs. Latent TB Infection in Pregnancy

Feature Active TB Latent TB Infection (LTBI)
Contagiousness Potentially contagious, especially pulmonary TB Not contagious
Symptoms Cough, fever, night sweats, weight loss, fatigue No symptoms
Diagnostic Tests Positive TST/IGRA, abnormal chest X-ray, positive sputum culture Positive TST/IGRA, normal chest X-ray, negative sputum studies
Treatment in Pregnancy Multi-drug regimen (typically RIPE) INH monotherapy with pyridoxine
Treatment Duration 6-9 months (longer for drug-resistant TB) 9 months
Maternal-Fetal Risk High risk if untreated; low risk if properly treated Low risk (risk is of future reactivation)
Breastfeeding Compatible after 2 weeks of effective therapy No restrictions
Newborn Management Evaluation for congenital TB; possible separation; INH prophylaxis Routine newborn care; no special precautions needed

Extrapulmonary TB vs. Pulmonary TB in Pregnancy

Feature Pulmonary TB Extrapulmonary TB
Primary Site Lungs Lymph nodes, pleura, genitourinary tract, bones, meninges, etc.
Contagiousness Potentially contagious via airborne route Generally not contagious (except laryngeal TB)
Common Symptoms Cough, hemoptysis, chest pain, dyspnea Site-specific (e.g., lymphadenopathy, bone pain, neurological symptoms)
Diagnosis Sputum studies, chest X-ray Site-specific samples, imaging, biopsies
Treatment Standard RIPE regimen Similar to pulmonary TB but may require longer duration
Infection Control Airborne precautions until non-infectious Standard precautions usually sufficient
Pregnancy Impact Respiratory compromise may affect oxygenation Depends on site; genital TB may affect fertility

Common Pitfalls in Managing TB during Pregnancy

  • Pitfall: Delaying chest X-ray due to radiation concerns. Correction: A single chest X-ray with abdominal shielding poses minimal risk to the fetus and should not be delayed if TB is suspected.
  • Pitfall: Assuming pregnancy increases TB risk. Correction: Pregnancy itself does not increase susceptibility to TB infection but may increase risk of progression from latent to active disease.
  • Pitfall: Stopping TB treatment at delivery. Correction: TB treatment must continue for the full recommended duration regardless of delivery timing.
  • Pitfall: Avoiding TB medications due to pregnancy. Correction: Untreated TB poses greater risks to mother and fetus than potential medication side effects.
  • Pitfall: Automatic separation of mothers with TB from their newborns. Correction: Separation is only necessary if the mother has untreated TB or has received less than 2 weeks of effective therapy.

Study Tips

  • Focus on distinguishing between screening/diagnostic tests for TB and their interpretation during pregnancy.
  • Memorize the safety profile of first-line TB medications during pregnancy and lactation.
  • Understand the criteria for determining infectiousness and the need for separation of mother and newborn.
  • Review the pathophysiology of TB transmission, including vertical transmission mechanisms.

Key Points

  • For NCLEX questions about TB in pregnancy, remember that treatment should never be delayed due to pregnancy concerns.
  • When answering questions about newborn management, focus on the mother's treatment status and infectiousness rather than TB diagnosis alone.

Quick Check: Test Your Knowledge

  1. Which TB medication is contraindicated during pregnancy?
    • a) Isoniazid
    • b) Rifampin
    • c) Streptomycin
    • d) Ethambutol
  2. When can a mother with active pulmonary TB typically breastfeed without restrictions?
    • a) Immediately after delivery regardless of treatment
    • b) After receiving at least 2 weeks of effective therapy
    • c) Only after completing the full course of TB treatment
    • d) Breastfeeding is contraindicated with active TB
  3. What supplement must be given to pregnant women receiving isoniazid?
    • a) Folic acid
    • b) Vitamin D
    • c) Pyridoxine (Vitamin B6)
    • d) Iron

Self-Assessment Checklist

  • I can describe the pathophysiology of TB and its transmission during pregnancy
  • I understand the screening and diagnostic methods for TB during pregnancy
  • I can identify which TB medications are safe versus contraindicated during pregnancy
  • I know the management principles for a newborn exposed to maternal TB
  • I can differentiate between active TB and latent TB infection in pregnancy
  • I understand the infection control measures needed for pregnant women with TB
  • I can describe the potential maternal and fetal complications of TB during pregnancy

Remember: Understanding TB management during pregnancy is critical for protecting both mother and baby. Your knowledge in this area can significantly impact outcomes for these vulnerable patients. Keep focusing on the key principles of screening, diagnosis, treatment, and infection control to provide optimal care.

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.